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INTRODUCTION
Cancer is the most frequent cause of death in both develop-
ing and developed countries, including Korea (1). The neces-
sities for studying survival in patients with cancer include
monitoring the global effect of diagnostic and treatment im-
provements, establishing priorities for healthcare investment
and research, and estimating the potentialities for further im-
provement (2). A report on population-based survival from
cancer has not been published in Korea. However, there is a
program called Korea Central Cancer Registry (KCCR) pro-
gram, which has been collecting all cancer data on a routine
basis from nation-wide, hospital-based cancer registries in
various designated areas of the country since 1980 (3). Trends
in cancer prevalence in Korea could be obtained from this
database. 
The aims of this study were to present survival rates in Kore-
an cancer patients and to evaluate their age and gender dif-
ferences utilizing data from the KCCR program. 
MATERIALS AND METHODS
Study cohort
The KCCR Program began in 1980 at 47 resident-training
general hospitals in Korea, and was expanded to 159 hospi-
tals, including almost all university hospitals (3). These hos-
pital-based reports were estimated to cover about 80 percent of
newly diagnosed malignancies in Korea. Survival analyses were
carried out with data collected under the KCCR Program,
which included all cancer patients diagnosed from January 1,
1997 to December 31, 1997. We have analyzed the effects of
age at diagnosis and sex on cancer survival from the cancer reg-
istry data of 64,240 Korean patients diagnosed of cancer in
1997, and compared them with the U.S.A. data (4). For each
patient, date of birth, date of diagnosis, age at diagnosis, gender,
address, primary site of cancer by ICD-O/2 (Oncology) code,
histological verification, and morphology were recorded. Age
at diagnosis was calculated based on the date of diagnosis in
KCCR data and was classified into the following 5-yr age
groups: 0-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39,
40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 74-79,
and 80 or over. The cancers were microscopically confirmed
in 85.1% of cases, and in cases of multiple tumors, only the
initially diagnosed tumor was included. Registered cancer data
were matched with vital status (alive/dead) from the national
population files. The vital status of each registered case was
verified until December 31, 1999. The follow-up of patients
could be regarded as practically complete for cancer registry
because we updated the vital status of patients through the na-
tional population files, such as the data from the Ministry of
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Survival of All Cancer Patients in Korea through 2-Year Follow-Up
Cancer is the most frequent cause of death in both developing and developed
countries, including Korea. The aim of this study was to present survival rates of
Korean cancer patients. Survival analysis was carried out with data collected under
the Korea Central Cancer Registry Program, which included all cancer patients
diagnosed from January 1, 1997 to December 31, 1997. We have analyzed the
effects of age at diagnosis and sex on cancer survival from the cancer registry data
of 64,240 Korean patients diagnosed of cancer in 1997. The overall survival rate
of all Korean cancer patients (both men and women) was 67% at 1 yr and 57% at
2 yr. The 1- and 2-yr survival rates for all cancers in men were 58% and 47%,
respectively, while those in women were 77% and 69%, respectively. Men had a
lower survival rate than women in most malignancies. The pancreatic cancer
was shown the lowest 1-yr survival rate. 
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Statistical methods
Cumulative observed survival rates (OSR) were calculated
by the life table method. To estimate the relative risk (RR)
of sex and age against survival rate, the data were analyzed by
means of Cox's proportional hazard model using SAS release
6.12. And for the international comparison of survival rates,
the relative survival rates at 1 and 2 yr from diagnosis were
computed for patients (4). The relative survival rate (RSR)
is defined as the ratio of the survival probability of a cancer
patient to the survival probability for an individual from the
general population having the same set of prognostic factors
for death: sex, age, and time period (5). It was expressed by
percents. 
RESULTS
Overall Survivals
Fig. 1 shows the overall survival curve for men and women
observed for 2 yr. Women showed a higher OSR than men
throughout the period. The OSR of all cancer patients (both
males and females) was 67% at 1 yr and 57% at 2 yr. The
OSR was 58% in men and 77% in women at 1 yr from diag-
nosis. At 2 yr, the OSR decreased to 47% in men and 69%
in women. The RR of dying within 2 yr for women was 0.49
when that for men were considered to be 1.0 (Table 1). 
Overall survival rate showed some striking differences ac-
cording to the primary sites of neoplasm (Table 2). Pancre-
atic cancer had the lowest 1-yr OSR of 24%, followed by
malignancy of unknown origin (33%), gallbladder cancers
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0-4 226 0.64 83 74 1.0 164 0.57 82 74 1.0
5-9 124 0.35 78 71 1.15 (0.75-1.76) 109 0.38 83 75 0.75 (0.46-1.22)
10-14 131 0.37 81 - 1.12 (0.73-1.71) 109 0.38 84 80 0.71 (0.43-1.18)
15-19 210 0.59 76 67 1.46 (1.03-2.07) 208 0.72 85 76 0.82 (0.55-1.23)
20-24 216 0.61 69 62 1.82 (1.30-2.55) 399 1.17 88 84 0.52(0.35-0.78)
25-29 367 1.04 71 64 1.74 (1.27-2.37) 820 2.84 89 85 0.53 (0.38-0.74)
30-34 616 1.74 68 60 1.88 (1.41-2.52) 1,608 5.56 89 84 0.56 (0.41-0.77)
35-39 1,251 3.54 68 60 1.94 (1.47-2.57) 2,694 9.32 91 86 0.49 (0.36-0.67)
40-44 1,844 5.22 66 57 2.14 (1.63-2.81) 2,958 10.23 89 84 0.59 (0.44-0.79)
45-49 2,480 7.02 62 51 2.50 (1.91-3.28) 2,785 9.63 85 79 0.75 (0.56-1.01)
50-54 3,550 10.05 61 51 2.57 (1.96-3.35) 2,793 9.66 82 75 0.95 (0.71-1.28)
55-59 5,768 16.33 60 49 2.69 (2.06-3.51) 3,379 11.69 78 70 1.19 (0.88-1.59)
60-64 6,145 17.39 58 46 2.90 (2.22-3.78) 3,387 11.72 73 65 1.41 (1.06-1.90)
65-69 5,140 14.55 55 43 3.16 (2.42-4.12) 2,976 10.29 66 57 1.84 (1.37-2.47)
70-74 3,844 10.88 52 40 3.46 (2.64-4.51) 2,293 7.93 59 49 2.36 (1.76-3.17)
75-79 2,318 6.56 46 35 3.97 (3.04-5.20) 1,412 4.88 52 40 2.93 (2.18-3.95)
80- 1,099 3.11 41 30 4.65 (3.54-6.11) 877 3.03 41 32 3.85 (2.86-5.20)
Total 35,239 55.00 58 47 1.0* 28,911 45.00 77 69 0.49*(0.48-0.51)
Age
(yr) No. % 1-yr SR 2-yr SR RR (95%CI) No. % 1-yr SR 2-yr SR RR (95%CI)
Male Female
Table 1. Overall survival rates (OSR, %) according to sex and age categories
*The relative risk of dying within 2 yr for women was calculated with the reference value of 1.0 for men.
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Fig. 1. Overall 2-yr survival rates for all cancers in Korean men
and women between 1997-1999.
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Fig. 2. Overall 1- and 2-yr survival rates for all cancers in Korean
men and women by age and sex between 1997-1999.
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Age (yr)(35%), liver cancer (39%), lung cancer (40%), and esophageal
cancer (44%). These cancers comprised 32.1% of all cancers.
The 2-yr OSR was similar in order except for the fact that
lung cancer showed a slightly worse survival (26%) than liver
and gallbladder cancers (29% for both).
Age-related differences
The 1- and 2-yr OSR for men and women in 5-yr age
groups are given in Table 1. The OSR showed different re-
sults between men and women (Fig. 2). With reference value
of 1.0 for the 0-4 yr age group, the 2-yr survival rate gener-
ally decreased with age in men. But in women, the OSR began
to increase around the 20-24 yr-age group, remained rela-
tively steady thereafter, and started to decrease around the
age of menopause (after 45).
Gender-related differences
Table 3 shows the OSR of tumor-specific deaths at 1 and 2
yr from the time of diagnosis for both men and women. Con-
sidering the overall age-adjusted survival, the risk of dying
was similar in men and women for most malignancies, except
for cancers of the esophagus, larynx, bladder, breast, and skin. 
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All C00-C97 61.7 (61.2, 62.3) 78.8 (78.3, 79.3)
Head & Neck C00-C14 76 .0  (73.1, 78.9) 85.2 (81.1, 89.2)
Esophagus C15 48.0 (45.0, 50.9) 43.4  (33.4, 53.3)
Stomach C16 70.4 (69.4, 71.4) 70.2 (68.8, 71.6)
Colo-rectum* C18-20 84.1 (82.7, 85.5) 83.1 (81.6, 84.7)
Liver C22.0 43.1 (41.7, 44.5) 47.3 (44.5, 50.0)
Pancreas C25 26.8 (23.5, 30.0) 26.7 (23.0, 30.4)
Bronchus & lung C34 43.4 (42.0, 44.7) 46.1 (43.6, 48.6)
Breast C50 - 96.9 (96.3, 97.5)
Cervix uteri C53 - 96.2 (95.7,  96.7)
Prostate C61 91.9 (89.2, 94.6) -
Kidney C64 90.8 (88.8, 92.7) 83.1 (77.9, 88.3)
Thyroid C73 94.8 (92.0, 97.6) 97.6 (96.8, 98.5)
Site ICD-10
Male Female
RSR (95% CI)
� RSR (95% CI)
�
Table 4. Relative survival rates (RSR, %) of first year in Koreans
according to the primary sites of neoplasm and sex 
*Age-trucated 0-84, 
� 95% Confidence Interval of Age-adjusted RSR.
Oral cavity & pharynx
C00-C14 1,269 2.1 75 61
Tongue C02 172 - 79 66
Mouth C03-C06 246 - 72 57
Pharynx C10-C13 459 - 70 56
Esophagus C15 1,254 2.1 44 30
Stomach C16 13,632 22.9 67 57
Colon C18 2,646 4.4 78 69
Rectum C20 2,618 4.4 82 71
Liver & intrahepatic bile duct
C22 7,347 12.3 39 29
liver cell C22.0 6,279 - 41 31
Gallbladder C23 794 1.3 35 29
Pancreas C25 1,304 2.2 24 17
Larynx C32 750 1.3 84 73
Bronchus & lung C34 7,399 12.4 40 26
Bone & cartilage C40-C41 358 0.6 78 70
Hematopoietic & reticular
C42 1,662 2.8 59 47
Skin C44 763 1.3 86 78
Breast C50 3,853 6.5 96 91
Cervix uteri C53 6,083 10.2 95 92
Ovary C56 1,037 1.7 84 76
Prostate C61 752 1.3 84 71
Kidney C64 897 1.5 78 71
Bladder C67 1,459 2.4 84 76
Brain C71 718 1.2 64 53
Thyroid C73 1,938 3.3 96 95
MUO* C80 1,073 1.8 33 24
Site ICD-10 No. % 1-yr SR 2-yr SR
Table 2. Overall survival rates (OSR, %) according to the prima-
ry sites of neoplasms
Oral cavity & pharynx
C00-C14 73 57 83 74
Tongue C02 80 65 73 65
Mouth C03-C06 67 33 87 78
Pharynx C10-C13 66 53 86 69
Esophagus C15 44 30 38 29
Stomach C16 67 56 68 58
Colon C18 78 69 77 69
Rectum C20 82 69 83 74
Liver & intrahepatic bile duct
C22 39 28 42 31
liver cell C22.0 41 30 46 34
Gallbladder C23 37 31 34 28
Pancreas C25 24 17 24 17
Larynx C32 83 72 88 83
Bronchus & lung C34 39 24 43 30
Bone & cartilage C40-C41 78 71 75 68
Hematopoietic & reticular
C42 58 46 60 49
Skin C44 83 75 89 83
Breast C50 95 82 96 91
Cervix uteri C53 --95 92
Ovary C56 --84 76
Prostate C61 84 71 --
Kidney C64 77 70 78 72
Bladder C67 85 78 79 68
Brain C71 63 52 66 55
Thyroid C73 93 90 97 96
MUO* C80 29 22 38 27
Site ICD-10
Male Female
1-yr SR 2-yr SR 1-yr SR 2-yr SR
Table 3. Overall survival rates (OSR, %) according to the primary
sites of neoplasms and sex
*Malignant neoplasm with Unknown Origin.
*Malignant neoplasm with Unknown Origin.Relative survivals
Table 4 and 5 shows RSR estimated at 1 and 2 yr, respec-
tively, for each cancer sites in Korea and U.S.A. For all can-
cers combined, the 1-yr RSR of men and women in Korea
was 61.7% and 78.8%, respectively. The 2-yr RSR was 50.7%
and 71.8 % for Korean men and women, respectively. 
DISCUSSION
Monitoring the survival trends of cancer patients is an es-
sential component of the evaluation of progress against can-
cers (6). This study might have some limitations because data
from the KCCR Program were hospital-based rather than
population-based. The typical biases of clinical survey, partic-
ularly the ‘case selection bias' could have been a limitation.
The second was that the cases registered through death cer-
tificates only (DCO) were not included in the analysis because
the KCCR Program is not a type of the population-based
cancer registry. The third question might be that whether
or not KCCR program data could represent the whole pop-
ulation (7, 8). However, the number of patients included in
these nation-wide, hospital-based reports was estimated to
represent about 80 percent of newly diagnosed malignancy
patients in Korea (3). And follow-up could be regarded as
practically complete, since the record linkage was based on
personal identification numbers and complete national reg-
isters on population. Thus, it seems reasonable to conclude
that this study provides useful information regarding cancer
control in Korea. 
In the present, women had significantly better survival rates
than men at both 1 yr and 2 yr from the diagnosis of cancer.
Women generally have a much longer life expectancy than
men. Several earlier observations suggested that this female
advantage is also present in cancer patients, even after adjust-
ing for competing mortality (9). It is possible that behavioral,
environmental, and genetic factors and their complex inter-
relations, which may influence the cancer prognosis, play a
role in determining the survival differences between the gen-
ders found in this study. For all cancers combined, women
had a much better prognosis than men with a RR of death
within 2 yr of cancer diagnosis of 0.49. However, whether
the females actually survive cancer better than males remains
to be determined. Part of the female advantage was explained
by the higher frequency of the smoking-related cancers (e.g.,
lung, pancreas, and esophagus), which have poor prognosis,
in men (9). Other fatal malignancies such as stomach and
liver cancers are also more common in men (10). However,
in our study, only lung cancer revealed a significant difference.
Furthermore, different histotypes and sub-site distributions
between men and women were considered to be the factors
contributing to the sex-related differences in survival of pa-
tients with cancers at certain sites (9). In our study, the risk
of death for women was significantly lower for cancers of the
oral cavity and pharynx, larynx, skin, and breast. In contrast,
for bladder cancer, the risk of death was significantly higher
for women. As mentioned above, these results might be ex-
plained by gender differences in sub-site distributions (oral
cavity, pharynx, and larynx) and by the differences in the stage
at diagnosis (presumably breast, skin, and bladder). The longer
survival for bladder cancer among men could be explained
by a higher frequency of non-invasive cancers in men than
in women (9). 
There was a decreasing tendency of overall survival rate with
increasing age both at 1 and 2 yr from diagnosis in male patients.
These findings are consistent with other population-based
reports on a large number of cases (11). The risk of death is
likely to depend on the stage distribution of cases at diag-
nosis, and other studies have shown that the proportion of
advanced cancers increases with age (12). In female patients,
there was a different trend. The survival rates slowly
increased from the 20-24 until 45-49 age group, and start-
ed to decrease thereafter. This pattern suggests a correlation
between female sex hormones and the survival from cancer.
It was suggested that female sex hormones might be able to
prevent the establishment of distant metastases in certain
malignant diseases (9). It may also be due to the fact that
the distribution of primary sites of cancer with prognostic
variations is different between the young age group and the
old age group. 
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